hello im second year mbbs student. tomorrow ive practical exam on p drug in pharmacology. give the p drug list and drug of choice for Stable angina
Reading File
Finding Sources
Finding Sources
Searching the Web
P drug concept pharmacology MBBS practical exam stable angina drug of choice
Finding Sources
Finding Sources
Reading Web Page
P drug stable angina drug of choice selection
Finding Sources
Finding Sources
Searching the Web
P drug list MBBS pharmacology practical atenolol metoprolol stable angina selection criteria WHO guide
Reading File
Reading File
Reading File
Reading File
Reading File
I now have all the information needed to give you a thorough, exam-ready answer. Here it is:
π P-Drug Concept β Pharmacology Practical (MBBS)
What is a P-Drug?
A P-Drug (Personal Drug) is a drug you personally select as a first-choice drug for a given condition, based on four criteria:
| Criteria | Meaning |
|---|---|
| Efficacy | Proven therapeutic effect for the condition |
| Safety | Acceptable side effect and toxicity profile |
| Suitability | Appropriate for the patient (age, co-morbidities, contraindications) |
| Cost | Affordable and accessible |
The concept comes from the WHO Guide to Good Prescribing β the idea is that every doctor should have a personal formulary of go-to drugs for common conditions.
Stable Angina β Drug of Choice (P-Drug)
β P-Drug: Atenolol (or Metoprolol)
Class: Cardioselective Ξ²β-blocker
Why it is the P-Drug for stable angina:
| Criteria | Justification |
|---|---|
| Efficacy | Reduces heart rate, cardiac output, and BP β β myocardial Oβ demand β prevents anginal attacks. Best evidence for reducing MI and mortality. |
| Safety | Ξ²β-selective β less risk of bronchospasm than non-selective agents (propranolol). Well-tolerated long-term. |
| Suitability | Once-daily dosing (atenolol 25β100 mg/day) β good compliance. Safe in diabetes, hypertension, post-MI. |
| Cost | Generic, inexpensive, widely available. |
Complete Drug List for Stable Angina (For the Exam)
1. π‘ Nitrates β Symptomatic Relief
| Drug | Use | Route |
|---|---|---|
| Glyceryl trinitrate (GTN/Nitroglycerin) | Acute attack β 1st choice for relief | Sublingual tablet/spray |
| Isosorbide dinitrate (ISDN) | Prophylaxis | Oral |
| Isosorbide mononitrate (ISMN) | Prophylaxis (active metabolite, better bioavailability) | Oral |
Mechanism: Releases NO β β cGMP β venodilation β β preload β β cardiac work β β Oβ demand. Also dilates coronaries.
Side effects: Headache, orthostatic hypotension, reflex tachycardia.
Nitrate tolerance: Prevented by providing a nitrate-free interval of 8β12 hours.
2. π΅ Beta-Blockers β P-Drug / First-Line Prophylaxis
| Drug | Selectivity | Dose |
|---|---|---|
| Atenolol β P-drug | Ξ²β-selective | 25β100 mg OD |
| Metoprolol | Ξ²β-selective | 25β100 mg BD |
| Propranolol | Non-selective | 40β80 mg BDβTDS |
Mechanism: Block Ξ²β β β HR, β contractility, β BP β β myocardial Oβ demand.
Contraindications: Asthma, complete heart block, severe bradycardia, decompensated heart failure.
3. π Calcium Channel Blockers (CCBs)
| Drug | Type | Key Feature |
|---|---|---|
| Amlodipine | Dihydropyridine (DHP) | Vasodilation > cardiac effect; safe with beta-blockers |
| Nifedipine (long-acting) | DHP | Vasodilation; avoid prompt-release form |
| Verapamil | Non-DHP | β HR + vasodilation; avoid with beta-blockers |
| Diltiazem | Non-DHP | β HR + vasodilation; avoid with beta-blockers |
When preferred over beta-blockers: Asthma, COPD, peripheral artery disease, vasospastic (Prinzmetal) angina, bradycardia/AV block.
4. π’ Newer / Add-on Drugs
| Drug | Mechanism | Use |
|---|---|---|
| Ranolazine | Inhibits late NaβΊ current β β intracellular CaΒ²βΊ β β diastolic tension | Add-on in refractory stable angina |
| Ivabradine | Blocks I_f (funny current) in SA node β β HR only | When beta-blockers are contraindicated/not tolerated |
| Nicorandil | KβΊ channel activator + nitrate-like | Vasodilation (dual action) |
| Trimetazidine | pFOX inhibitor β shifts metabolism away from fatty acid oxidation | Metabolic protection of ischemic myocardium |
5. π΄ Antiplatelet + Lipid-Lowering (Background Therapy)
| Drug | Role |
|---|---|
| Aspirin 75β150 mg/day | Antiplatelet β reduces MI risk in all IHD patients |
| Clopidogrel | Aspirin alternative if intolerant |
| Statins (e.g., Atorvastatin) | Plaque stabilization, LDL reduction, mortality benefit |
| ACE inhibitors/ARBs | If diabetes, hypertension, or LV dysfunction coexist |
Summary Table for Quick Revision
| Situation | Drug |
|---|---|
| Acute attack relief | GTN sublingual |
| Prophylaxis (P-Drug) | Atenolol (Ξ²-blocker) |
| Vasospastic angina | CCB (nifedipine/amlodipine) |
| Angina + asthma | CCB (not beta-blocker) |
| Angina + heart failure | Long-acting nitrate + amlodipine |
| Refractory angina | Add ranolazine or ivabradine |
| Angina + hypertension | Beta-blocker or CCB (dual benefit) |
| All IHD patients | Aspirin + Statin |
P-Drug Selection Steps (For the Practical Viva)
- Define the diagnosis β Stable angina
- State therapeutic objective β Prevent ischemia, relieve symptoms, reduce mortality
- Inventory possible drugs β Nitrates, Ξ²-blockers, CCBs
- Choose based on ESSC β Efficacy, Safety, Suitability, Cost
- Select P-Drug β Atenolol (or Metoprolol)
- Write prescription β Drug name, dose, route, frequency, duration
Good luck tomorrow! π― Remember: for the viva, always justify why your P-drug fits all four criteria β that's what examiners want to hear.
hello im second year mbbs student. tomorrow ive practical exam on p drug in pharmacology. give the p drug list and drug of choice for Osteoporosis
Finding Sources
Searching the Web
P drug osteoporosis MBBS pharmacology practical alendronate bisphosphonate drug of choice selection criteria
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive, textbook-sourced information. Here is your complete exam-ready answer:
π P-Drug Concept β Pharmacology Practical (MBBS)
Topic: Osteoporosis
What is a P-Drug? (Quick Recap)
A Personal Drug (P-Drug) is your first-choice drug for a condition, selected based on:
| Criteria | Meaning | |
|---|---|---|
| E | Efficacy | Proven to work |
| S | Safety | Acceptable side-effect profile |
| S | Suitability | Fits the patient (age, co-morbidities) |
| C | Cost | Affordable, accessible |
β P-Drug for Osteoporosis: Alendronate
Class: Bisphosphonate (nitrogen-containing)
Why Alendronate is the P-Drug:
| Criteria | Justification |
|---|---|
| Efficacy | Proven to increase BMD (bone mineral density) at lumbar spine and hip; significantly reduces vertebral AND non-vertebral fractures |
| Safety | Well-established profile; GI side effects manageable with correct administration technique |
| Suitability | Oral tablet; once-weekly dosing (70 mg/week) β excellent compliance; first-line for postmenopausal osteoporosis |
| Cost | Generic, widely available, inexpensive |
Dose: 70 mg orally once weekly (or 10 mg once daily)
Complete Drug List for Osteoporosis
π΅ 1. Bisphosphonates β First-Line / P-Drug Class
Mechanism: Bind to hydroxyapatite in bone β inhibit osteoclast activity β β bone resorption
| Drug | Route | Frequency |
|---|---|---|
| Alendronate β P-Drug | Oral | Daily or Weekly |
| Risedronate | Oral | Daily, Weekly, or Monthly |
| Ibandronate | Oral / IV | Monthly oral / Every 3 months IV |
| Zoledronic acid | IV infusion | Once yearly |
Antiresorptive potency (relative):
Etidronate (1) < Pamidronate (100) < Alendronate (1000) < Risedronate (5000) < Ibandronate = Zoledronic acid (10,000)
Key Administration Rules (must-know for exam!):
- Take with plain water only (6β8 oz)
- Take 30 min before food, drink, or medications
- Remain upright for at least 30 minutes after taking (prevent esophageal ulceration)
Side Effects:
- GI: Diarrhea, abdominal pain, esophagitis/esophageal ulcers
- Osteonecrosis of the jaw (ONJ) β rare, especially with IV forms
- Atypical subtrochanteric femoral fractures β with long-term use
- Avoid in severe renal impairment (CrCl <35 mL/min)
π 2. RANKL Inhibitor
Denosumab β Monoclonal antibody against RANKL
Mechanism: Blocks RANKL β prevents activation of RANK on osteoclasts β β osteoclast formation and bone resorption
Use: Postmenopausal osteoporosis; glucocorticoid-induced osteoporosis; men with osteoporosis
Dose: 60 mg subcutaneous injection every 6 months
Considered alternative first-line, especially in patients with renal impairment (where bisphosphonates are contraindicated)
β οΈ Important: Do NOT stop denosumab abruptly β causes rebound bone resorption. Must transition to a bisphosphonate after stopping.
π‘ 3. Parathyroid Agents (Anabolic β Bone FORMING)
Used only in very high fracture risk or failed antiresorptive therapy
| Drug | Type | Dose |
|---|---|---|
| Teriparatide | Recombinant PTH (1-34) | 20 mcg SC daily |
| Abaloparatide | PTH-related peptide analog | 80 mcg SC daily |
Mechanism: Stimulate osteoblast activity β β bone formation and strength
Max duration: 2 years (risk of osteosarcoma in rats; contraindicated in patients at risk)
After completing therapy β must switch to an antiresorptive (bisphosphonate) to maintain gains.
π’ 4. Sclerostin Inhibitor (Anabolic + Antiresorptive)
Romosozumab β Monoclonal antibody against sclerostin
Mechanism: Inhibits sclerostin β β osteoblast activity (bone formation) + β osteoclast activity (dual action)
Dose: Once-monthly SC injection Γ 12 months
Use: Postmenopausal women at very high fracture risk
β οΈ Avoid in patients with recent MI or stroke (cardiovascular risk)
π΄ 5. Selective Estrogen Receptor Modulators (SERMs)
Raloxifene β Acts as estrogen agonist at bone, antagonist at breast/uterus
Mechanism: β bone resorption (like estrogen) + reduces breast cancer risk
Use: Prevention and treatment of postmenopausal osteoporosis
Reduces: Vertebral fractures (but NOT hip fractures β unlike bisphosphonates)
Contraindication: History of DVT/PE (β thromboembolic risk)
π£ 6. Calcitonin
Salmon calcitonin β intranasal spray or SC injection
Mechanism: Directly inhibits osteoclasts β β bone resorption
Unique property: Analgesic effect for acute painful vertebral fractures
Use: Last resort β less effective than other agents; associated with increased malignancy risk with long-term use. Only when all other options are inappropriate.
β¬ 7. Non-Pharmacological / Supportive (Always Mention!)
| Agent | Role |
|---|---|
| Calcium (Carbonate/Citrate) | 1000β1200 mg/day; foundation of all osteoporosis management |
| Vitamin D (D3 = Cholecalciferol) | 600β800 IU/day; essential for calcium absorption |
| Weight-bearing exercise | Stimulates bone formation |
| Smoking cessation, β alcohol | Reduce bone loss |
Summary Table β Quick Revision
| Situation | Drug of Choice |
|---|---|
| Postmenopausal osteoporosis (P-Drug) | Alendronate 70 mg/week |
| Can't tolerate oral bisphosphonate | Zoledronic acid IV or Denosumab SC |
| Renal impairment (severe) | Denosumab (no renal dose adjustment needed) |
| Very high fracture risk | Teriparatide or Romosozumab |
| Acute painful vertebral fracture | Calcitonin (analgesic) |
| Osteoporosis + breast cancer risk | Raloxifene |
| Glucocorticoid-induced osteoporosis | Bisphosphonate (alendronate/risedronate) |
| All patients | Calcium + Vitamin D supplementation |
Drugs That Cause Osteoporosis (Bonus for Viva!)
Glucocorticoids, furosemide, heparin, phenytoin, PPIs, SSRIs, aromatase inhibitors, thiazolidinediones, excessive thyroid replacement
P-Drug Viva Answer Format
"My P-Drug for osteoporosis is Alendronate, a bisphosphonate. It is efficacious β proven to reduce vertebral and non-vertebral fractures and increase BMD. It is safe when taken correctly. It is suitable β available as a once-weekly oral tablet with good compliance. And it is cost-effective as a generic drug. Dose: 70 mg once weekly orally, taken 30 minutes before food with plain water, while remaining upright."
All the best for your exam tomorrow! π―
β Sources: Lippincott Illustrated Reviews Pharmacology; Harrison's Principles of Internal Medicine 22E
hello im second year mbbs student. tomorrow ive practical exam on p drug in pharmacology. give the p drug list and drug of choice for Osteoarthritis of both knees
Finding Sources
Searching the Web
P drug osteoarthritis knee MBBS pharmacology practical paracetamol NSAIDs drug of choice selection
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching the Web
drug of choice osteoarthritis knee pharmacology ibuprofen celecoxib paracetamol intraarticular injection management stepwise
Finding Sources
Finding Sources
Reading File
Reading File
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.